# Exavir Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exavir-therapeutics

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.exavirtherapeutics.com
- Total disclosed funding: $4M
- Latest round: Seed (May 23, 2022)
- Investors on record: 2

## About

Based in California, US, and founded in 2022 by its MD, Howard Gendelman, Benson Edagwa, and President, Alborz Yazdi, Exavir Therapeutics Inc., operates as a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. In May 2023, Exavir Therapeutics raised USD 4 million in seed funding led by investor AlleyCorp. As of 2023, the company is led by its MD, Jeff Murray.

The company offers a molecule platform technology used to deliver nanoparticles to patients with HIV, opioid use disorder, and schizophrenia.

The company uses lipid nanoparticle technology to transform dolutegravir into an ultra-long-acting parenteral prodrug formulation.

The company plans to use the May 2023 funding to expand its development initiatives.

## Funding rounds

- Seed, May 23, 2022, $4M — Gilead Sciences, Inc., AlleyCorp

## Investors

- Gilead Sciences, Inc. — Seed
- AlleyCorp — Seed